MITF Promotes Cell Growth, Migration and Invasion in Clear Cell Renal Cell Carcinoma by Activating the RhoA/YAP Signal Pathway.
MITF
RhoA
YAP
cell cycle
invasion
migration
proliferation
renal cell carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Jun 2021
11 Jun 2021
Historique:
received:
04
05
2021
revised:
25
05
2021
accepted:
08
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Microphthalmia-associated transcription factor (MITF) is a basic helix-loop-helix leucine zipper transcription factor involved in the lineage-specific regulation of melanocytes, osteoclasts and mast cells. MITF is also involved in the progression of melanomas and other carcinomas, including the liver, pancreas and lung. However, the role of MITF in clear cell renal cell carcinoma (ccRCC) is largely unknown. This study investigates the functional role of MITF in cancer and the molecular mechanism underlying disease progression in ccRCC. MITF knockdown inhibited cell proliferation and shifted the cell cycle in ccRCC cells. In addition, MITF knockdown reduced wound healing, cell migration and invasion compared with the controls. Conversely, MITF overexpression in SN12C and SNU482 cells increased cell migration and invasion. Overexpression of MITF activated the RhoA/YAP signaling pathway, which regulates cell proliferation and invasion, and increased YAP signaling promoted cell cycle-related protein expression. Additionally, tumor formation was impaired by MITF knockdown and enhanced by MITF overexpression in vivo. In summary, MITF expression was associated with aggressive tumor behavior, and increased the migratory and invasive capabilities of ccRCC cells. These effects were reversed by MITF suppression. These results suggest that MITF is a potential therapeutic target for the treatment of ccRCC.
Identifiants
pubmed: 34208068
pii: cancers13122920
doi: 10.3390/cancers13122920
pmc: PMC8230652
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Foundation of Korea
ID : NRF-2017R1D1A1B04034638, NRF-2017R1A5A2015385
Organisme : Korea Health Industry Development Institute
ID : HR20C0025
Pays : Republic of Korea
Références
Oncol Lett. 2019 Mar;17(3):3211-3218
pubmed: 30867751
Lab Invest. 2017 Jun;97(6):649-656
pubmed: 28263292
Carcinogenesis. 2011 Mar;32(3):389-98
pubmed: 21112960
Tohoku J Exp Med. 2017;242(4):291-302
pubmed: 28794318
Oncogenesis. 2020 Mar 20;9(3):36
pubmed: 32198343
Cancer Cell. 2004 Dec;6(6):565-76
pubmed: 15607961
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Nat Commun. 2016 Jun 13;7:ncomms11840
pubmed: 27291620
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9782-7
pubmed: 23716662
Cell Stress. 2018 Aug 14;2(9):233-235
pubmed: 31225491
Gut. 2018 Sep;67(9):1692-1703
pubmed: 28866620
Cancer Metastasis Rev. 2017 Mar;36(1):77-90
pubmed: 28283772
Sci Rep. 2019 Jul 19;9(1):10509
pubmed: 31324828
Transl Oncol. 2014 Apr;7(2):309-21
pubmed: 24913676
Biomarkers. 2005 Jul-Aug;10(4):258-94
pubmed: 16191485
Nat Cell Biol. 2015 Sep;17(9):1218-27
pubmed: 26258633
PLoS One. 2013 Jun 27;8(6):e67294
pubmed: 23826258
Trends Cell Biol. 2007 Feb;17(2):58-64
pubmed: 17161947
Sci Rep. 2019 Dec 2;9(1):18100
pubmed: 31792315
Cell. 2012 Aug 17;150(4):780-91
pubmed: 22863277
Pigment Cell Res. 2006 Aug;19(4):290-302
pubmed: 16827748
Lancet Oncol. 2014 Apr;15(4):e170-7
pubmed: 24694640
Nature. 2002 Dec 12;420(6916):629-35
pubmed: 12478284
Urology. 2021 Mar;149:89-97
pubmed: 33242557
Clin Transl Oncol. 2019 Jul;21(7):910-923
pubmed: 30565087
Oncotarget. 2017 Jun 27;8(42):71954-71964
pubmed: 29069760
Cell. 1993 Jul 30;74(2):395-404
pubmed: 8343963
Nature. 2005 Feb 17;433(7027):764-9
pubmed: 15716956
J Biol Chem. 1993 Oct 5;268(28):20687-90
pubmed: 8407885
Trends Mol Med. 2006 Sep;12(9):406-14
pubmed: 16899407
Cancers (Basel). 2019 Sep 30;11(10):
pubmed: 31575084
Cancer Manag Res. 2020 Jul 29;12:6563-6573
pubmed: 32801894
Afr J Paediatr Surg. 2011 Sep-Dec;8(3):317-9
pubmed: 22248899
Nature. 2011 Jun 08;474(7350):179-83
pubmed: 21654799
PLoS Pathog. 2020 Jun 18;16(6):e1008624
pubmed: 32555725
Prog Urol. 2008 May;18(5):275-80
pubmed: 18538271
J Cell Sci. 2001 Aug;114(Pt 15):2713-22
pubmed: 11683406
Curr Opin Cell Biol. 2008 Dec;20(6):638-46
pubmed: 18955139
Mol Cancer Res. 2016 Feb;14(2):127-40
pubmed: 26432795
Oncogene. 2016 Aug 4;35(31):4048-57
pubmed: 26657153
Physiol Rev. 2014 Oct;94(4):1287-312
pubmed: 25287865
Genes Dev. 2006 Dec 15;20(24):3426-39
pubmed: 17182868
J Cell Biol. 2011 Nov 14;195(4):595-603
pubmed: 22084308
Nature. 2015 Aug 20;524(7565):361-5
pubmed: 26168401
Oncogene. 2011 Jun 23;30(25):2810-22
pubmed: 21317925
Hum Pathol. 2008 Nov;39(11):1582-9
pubmed: 18703216
Int J Cancer. 2004 Dec 10;112(5):777-86
pubmed: 15386385
Cancer Res. 2019 Dec 15;79(24):6139-6152
pubmed: 31578200
J Cell Physiol. 2011 Apr;226(4):928-39
pubmed: 20945341
J Clin Oncol. 2006 Dec 10;24(35):5601-8
pubmed: 17158546
Nature. 2011 Oct 19;480(7375):94-8
pubmed: 22012259
Liver Int. 2012 Jan;32(1):38-47
pubmed: 22098159
Nat Rev Cancer. 2013 Apr;13(4):246-57
pubmed: 23467301